UK
Deutsch
Español
Italiano
Française
Русский
עברית
Portuguese
한국어
日本語
USA1,000 WOMEN TREATED WITH FIRST NON-INVASIVE SURGERY FOR UTERINE FIBROIDS
-ExAblate® 2000 offers women the only non-invasive option for treatment -
Haifa, Israel– June 7, 2005 - InSightec today announced that over 1,000 women with symptomatic uterine fibroids worldwide have now undergone treatment with ExAblate® 2000, its non-invasive treatment for symptomatic uterine fibroids, which the U.S. Food and Drug Administration (FDA) approved in October 2004. Trials are now underway to study the effectiveness of the ExAblate technology in the treatment of breast, bone, liver and brain tumors.
According to the U.S. National Institutes of Health, at least 25 percent of women, or thirteen million women in U.S., aged 25-50, suffer from uterine fibroids. These tumors can be as small as a pea or as large as a grapefruit and often cause heavy and extensive menstrual bleeding, pain or discomfort in the pelvis, pressure on the lower abdomen, bulk, and frequent urination, among other symptoms.
"We are pleased that more and more women are benefiting from this patient-friendly treatment for uterine fibroids, "Dr. Jacob Vortman, president and CEO, InSightec, said. "Until ExAblate, surgical treatment options for women were invasive, required hospital stays and at least a week of recovery. The ExAblate is an incisionless, out-patient procedure, with most women returning to normal activities within 1-2 days."
ExAblate is the first system to use the breakthrough MRgFUS technology which combines magnetic resonance imaging (MRI) -- to visualize tissues in the body, plan the treatment and monitor in real time treatment outcome -- and Focused Ultrasound energy waves to ablate the fibroid tissue. MR thermometry feedback, provided uniquely by the system, allows the physician to monitor and adjust the treatment to ensure that the targeted tumor is fully treated and all other tissue is avoided. sThe ExAblate 2000 is only compatible with GE Healthcare's SIGNA Magnetic Resonance systems.
Currently, nine major medical centers in the United States are equipped with the ExAblate 2000 System:
- Tower Beverly Radiology - Radnet in Beverly Hills, CA
- UCSD Medical Center in San Diego, CA
- Mayo Clinic in Rochester, MN
- University MRI in Boca Raton, FL
- The Lahey Clinic in Burlington, MA
- Brigham and Women's Hospital in Boston, MA
- The Johns Hopkins Hospital in Baltimore, MD
- Virtua Health in Voorhees, NJ
- Cornell Weill Medical Center, New York, NY
Internationally, systems are installed at these prestigious institutions:
- St. Mary's Hospital, Imperial College, London, UK
- Charite's Hospital, Humboldt University, Berlin, Germany
- Semmelweis University, Budapest, Hungary
- Sheba Medical Center, Tel Aviv, Israel
- Itabashi Chuo Medical Center, Tokyo, Japan
- Amour Clinic, Yokahama, Japan
- Shinsuma Hospital, Kobe, Japan
- Iseikai Hospital, Osaka, Japan
- Namba Breastopia Hospital, Miyazaki, Japan
Several more sites are expected to be installed in the U.S. by the end of 2005.
About InSightec
InSightec Image Guided Treatment Ltd. is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, private investors and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 100 employees and has invested more than $80 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/
Contact Information
For media inquiries, contact:
Previous
